Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours
Hester van Cruijsen, Giuseppe Giaccone(Cornell University), Carla M.L. van Herpen(Radboud University Nijmegen), O. Saunders(AstraZeneca (United Kingdom)), Petronella O. Witteveen(University Medical Center Utrecht), Cornelis J.A. Punt(Utrecht University), Emile E. Voest(University Medical Center Utrecht), Thomas A. Puchalski(Dana-Farber Cancer Institute), Juliane M. Jürgensmeier(AstraZeneca (United Kingdom)), Klaas Hoekman, Jane Robertson(Cancer Research UK), Martijn R. Meijerink(Amsterdam University Medical Centers)
Cited by 54
Related Papers
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
Direct detection of early-stage cancers using circulating tumor DNA
|Science Translational Medicine|2017|1.1k